Bajaj Healthcare Ltd (BAJH.NS) shares dropped 3.4% in pre-open trade on Wednesday, February 12, 2025, following the release of its Q3 FY25 results. Despite swinging to a profit of ₹11.7 crore from a loss in the previous year, investors seemed unimpressed. The company reported a 13.1% year-on-year revenue growth to ₹122.8 crore, driven by steady demand for its APIs and bulk drugs. However, the EBITDA margin slightly contracted to 17.7% from 18.1% a year ago. The stock's decline reflects investor concerns about margin pressure and growth sustainability in a competitive pharmaceutical landscape.
Sources: Reuters, CNBC-TV18, Economic Times